Approval

China clears Immunochina's CD19 CAR-T IM19 for relapsed large B-cell lymphoma

The NMPA approved IM19, an autologous CD19-directed CAR-T from Immunochina Pharmaceuticals, for adult large B-cell lymphoma that has relapsed or resisted two or more earlier systemic lines. It is the company's first marketed product. In the 96-patient confirmatory efficacy set, the three-month response rate was 58.3% and median progression-free survival was 5.98 months.

Written by Gosset from public sources. Source types: News article. Sources are available to Gosset users. Log in to see them.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call